NIKA NIKA PHARMACEUTICALS, INC revenue, earnings and financials
For the quarter ended June 30, 2026, NIKA PHARMACEUTICALS, INC reported revenue of n/a, net income of −$19.7K and diluted EPS of $0.00; for the fiscal year ended December 2025 revenue was n/a.
NIKA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$76.4K, net income −$76.4K (margin n/a), EPS $0.00
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$95.8K, net income −$95.8K (margin n/a), EPS $0.00
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$64.8K, net income −$64.8K (margin n/a), EPS $0.00
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$3.18M, net income −$3.18M (margin n/a), EPS $0.00
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$14.7K, net income −$14.7K (margin n/a), EPS $0.00
NIKA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$19.7K, EPS $0.00
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.4K, EPS $0.00
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$37.1K, EPS $0.00
- Quarter ended Sep 30, 2025: revenue n/a, net income −$8.00K, EPS $0.00
- Quarter ended Jun 30, 2025: revenue n/a, net income −$18.4K, EPS $0.00
- Quarter ended Mar 31, 2025: revenue n/a, net income −$12.9K, EPS $0.00
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$19.0K, EPS $0.00
- Quarter ended Sep 30, 2024: revenue n/a, net income −$8.37K, EPS $0.00
- Quarter ended Jun 30, 2024: revenue $156, net income −$22.5K, EPS $0.00
- Quarter ended Mar 31, 2024: revenue n/a, net income −$46.0K, EPS $0.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$25.0K, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$10.1K, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income −$10.1K, EPS $0.00
- Quarter ended Mar 31, 2023: revenue $0, net income −$19.6K, EPS $0.00
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$15.1K, EPS $0.00
- Quarter ended Sep 30, 2022: revenue n/a, net income −$6.34K, EPS $0.00
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.16M, EPS $0.00
- Quarter ended Mar 31, 2022: revenue $0, net income −$6.32K, EPS $0.00
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$26.1K, EPS $0.00
- Quarter ended Sep 30, 2021: revenue n/a, net income $2.70K, EPS $0.00
NIKA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$79.7K, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$155K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$64.8K, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $33.7K, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $14.7K, share buybacks n/a
NIKA balance sheet
- Jun 30, 2026: cash $2.93K, total assets $9.94K, total liabilities $341K, shareholders' equity −$331K
- Mar 31, 2026: cash $1.53K, total assets $20.6K, total liabilities $332K, shareholders' equity −$311K
- Dec 31, 2025: cash $1.89K, total assets $21.0K, total liabilities $319K, shareholders' equity −$298K
- Sep 30, 2025: cash $6.29K, total assets $23.6K, total liabilities $284K, shareholders' equity −$261K
- Jun 30, 2025: cash $15.6K, total assets $31.6K, total liabilities $284K, shareholders' equity −$253K
- Mar 31, 2025: cash $19.1K, total assets $35.0K, total liabilities $269K, shareholders' equity −$234K
- Dec 31, 2024: cash $2.08K, total assets $17.9K, total liabilities $239K, shareholders' equity −$221K
- Sep 30, 2024: cash $1.39K, total assets $1.39K, total liabilities $210K, shareholders' equity −$200K
Is NIKA profitable?
No. NIKA PHARMACEUTICALS, INC lost $78.1K over the last four quarters.
What is NIKA's EPS?
Diluted earnings per share over the last four quarters were $0.00; $0.00 in the latest quarter.